In­ter­cep­t's NASH hope­ful gets pre­lim­i­nary thumbs down in FDA brief­ing docs

The FDA has once again raised safe­ty con­cerns around the use of In­ter­cept’s obeti­cholic acid in NASH, con­clud­ing in brief­ing doc­u­ments ahead of an up­com­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.